Home/Filings/4/0001209191-16-107353

4//SEC Filing

Syndax Pharmaceuticals Inc 4

Accession 0001209191-16-107353

$SNDXCIK 0001395937operating

View on SEC.gov Company Profile

Filed

Mar 8, 7:00 PM ET

Accepted

Mar 9, 4:42 PM ET

Size

32.6 KB

Accession

0001209191-16-107353

Insider Transaction Report

Form 4

Period: 2016-03-08

Syndax Pharmaceuticals IncSNDX

GADICKE ANSBERT

10% Owner

Transactions

Conversion
Series A-1 Preferred Stock
2016-03-08−1,138,210→ 0 total(indirect: See footnote)
→ Common Stock (1,138,210 underlying)
Conversion
Common Stock
2016-03-08+1,138,210→ 1,138,210 total(indirect: See footnote)
Conversion
Series B-1 Preferred Stock
2016-03-08−718,396→ 0 total(indirect: See footnote)
→ Common Stock (718,396 underlying)
Conversion
Common Stock
2016-03-08+312,085→ 2,168,691 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+718,396→ 1,856,606 total(indirect: See footnote)
Conversion
Series C-1 Preferred Stock
2016-03-08−312,085→ 0 total(indirect: See footnote)
→ Common Stock (312,085 underlying)

KAILIAN VAUGHN M

10% Owner

Transactions

Conversion
Common Stock
2016-03-08+312,085→ 2,168,691 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2016-03-08−1,138,210→ 0 total(indirect: See footnote)
→ Common Stock (1,138,210 underlying)
Conversion
Common Stock
2016-03-08+1,138,210→ 1,138,210 total(indirect: See footnote)
Conversion
Series B-1 Preferred Stock
2016-03-08−718,396→ 0 total(indirect: See footnote)
→ Common Stock (718,396 underlying)
Conversion
Common Stock
2016-03-08+718,396→ 1,856,606 total(indirect: See footnote)
Conversion
Series C-1 Preferred Stock
2016-03-08−312,085→ 0 total(indirect: See footnote)
→ Common Stock (312,085 underlying)

MPM Asset Management Investors BV4 LLC

10% Owner

Transactions

Conversion
Common Stock
2016-03-08+718,396→ 1,856,606 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+1,138,210→ 1,138,210 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+312,085→ 2,168,691 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2016-03-08−1,138,210→ 0 total(indirect: See footnote)
→ Common Stock (1,138,210 underlying)
Conversion
Series C-1 Preferred Stock
2016-03-08−312,085→ 0 total(indirect: See footnote)
→ Common Stock (312,085 underlying)
Conversion
Series B-1 Preferred Stock
2016-03-08−718,396→ 0 total(indirect: See footnote)
→ Common Stock (718,396 underlying)

MPM BioVentures IV QP LP

10% Owner

Transactions

Conversion
Series B-1 Preferred Stock
2016-03-08−718,396→ 0 total(indirect: See footnote)
→ Common Stock (718,396 underlying)
Conversion
Series C-1 Preferred Stock
2016-03-08−312,085→ 0 total(indirect: See footnote)
→ Common Stock (312,085 underlying)
Conversion
Common Stock
2016-03-08+1,138,210→ 1,138,210 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+718,396→ 1,856,606 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+312,085→ 2,168,691 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2016-03-08−1,138,210→ 0 total(indirect: See footnote)
→ Common Stock (1,138,210 underlying)

Scopa James Paul

10% Owner

Transactions

Conversion
Series B-1 Preferred Stock
2016-03-08−718,396→ 0 total(indirect: See footnote)
→ Common Stock (718,396 underlying)
Conversion
Series C-1 Preferred Stock
2016-03-08−312,085→ 0 total(indirect: See footnote)
→ Common Stock (312,085 underlying)
Conversion
Common Stock
2016-03-08+718,396→ 1,856,606 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+312,085→ 2,168,691 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+1,138,210→ 1,138,210 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2016-03-08−1,138,210→ 0 total(indirect: See footnote)
→ Common Stock (1,138,210 underlying)

Foley Todd

10% Owner

Transactions

Conversion
Common Stock
2016-03-08+312,085→ 2,168,691 total(indirect: See footnote)
Conversion
Series B-1 Preferred Stock
2016-03-08−718,396→ 0 total(indirect: See footnote)
→ Common Stock (718,396 underlying)
Conversion
Common Stock
2016-03-08+718,396→ 1,856,606 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+1,138,210→ 1,138,210 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2016-03-08−1,138,210→ 0 total(indirect: See footnote)
→ Common Stock (1,138,210 underlying)
Conversion
Series C-1 Preferred Stock
2016-03-08−312,085→ 0 total(indirect: See footnote)
→ Common Stock (312,085 underlying)

MPM BioVentures IV GmbH & Co. Beteiligungs KG

10% Owner

Transactions

Conversion
Common Stock
2016-03-08+718,396→ 1,856,606 total(indirect: See footnote)
Conversion
Series B-1 Preferred Stock
2016-03-08−718,396→ 0 total(indirect: See footnote)
→ Common Stock (718,396 underlying)
Conversion
Common Stock
2016-03-08+1,138,210→ 1,138,210 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+312,085→ 2,168,691 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2016-03-08−1,138,210→ 0 total(indirect: See footnote)
→ Common Stock (1,138,210 underlying)
Conversion
Series C-1 Preferred Stock
2016-03-08−312,085→ 0 total(indirect: See footnote)
→ Common Stock (312,085 underlying)

MPM BioVentures IV GP LLC

10% Owner

Transactions

Conversion
Common Stock
2016-03-08+1,138,210→ 1,138,210 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+718,396→ 1,856,606 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+312,085→ 2,168,691 total(indirect: See footnote)
Conversion
Series B-1 Preferred Stock
2016-03-08−718,396→ 0 total(indirect: See footnote)
→ Common Stock (718,396 underlying)
Conversion
Series C-1 Preferred Stock
2016-03-08−312,085→ 0 total(indirect: See footnote)
→ Common Stock (312,085 underlying)
Conversion
Series A-1 Preferred Stock
2016-03-08−1,138,210→ 0 total(indirect: See footnote)
→ Common Stock (1,138,210 underlying)

MPM BioVentures IV LLC

10% Owner

Transactions

Conversion
Series C-1 Preferred Stock
2016-03-08−312,085→ 0 total(indirect: See footnote)
→ Common Stock (312,085 underlying)
Conversion
Common Stock
2016-03-08+1,138,210→ 1,138,210 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2016-03-08−1,138,210→ 0 total(indirect: See footnote)
→ Common Stock (1,138,210 underlying)
Conversion
Common Stock
2016-03-08+718,396→ 1,856,606 total(indirect: See footnote)
Conversion
Common Stock
2016-03-08+312,085→ 2,168,691 total(indirect: See footnote)
Conversion
Series B-1 Preferred Stock
2016-03-08−718,396→ 0 total(indirect: See footnote)
→ Common Stock (718,396 underlying)

MPM BioVentures IV Strategic Fund, L.P.

10% Owner

Transactions

Conversion
Common Stock
2016-03-08+312,085→ 2,168,691 total(indirect: See footnote)
Conversion
Series B-1 Preferred Stock
2016-03-08−718,396→ 0 total(indirect: See footnote)
→ Common Stock (718,396 underlying)
Conversion
Common Stock
2016-03-08+1,138,210→ 1,138,210 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2016-03-08−1,138,210→ 0 total(indirect: See footnote)
→ Common Stock (1,138,210 underlying)
Conversion
Common Stock
2016-03-08+718,396→ 1,856,606 total(indirect: See footnote)
Conversion
Series C-1 Preferred Stock
2016-03-08−312,085→ 0 total(indirect: See footnote)
→ Common Stock (312,085 underlying)

Footnotes (7)

[F1]The shares were converted as follows: 948,247 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 36,532 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG"), 26,964 by MPM Asset Management Investors BV4 LLC ("AM BV4") and 126,467 shares held by MPM BioVentures IV Strategic Fund, L.P. ("BV IV SF"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP, BV IV KG and BV IV SF and BV LLC is the manager of AM BV4. Ansbert Gadicke, Luke Evnin, Vaughn M. Kailian, James Paul Scopa and Todd Foley are the members of BV LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F2]The shares of Series A-1 Preferred Stock, Series B-1 Preferred Stock and Series C-1 Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date.
[F3]The shares are held as follows: 948,247 by BV IV QP, 36,532 by MPM BV IV KG, 26,964 by AM BV4 and 126,467 shares held by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F4]The shares were converted as follows: 598,509 by BV IV QP, 23,053 by BV IV KG, 17,013 by AM BV4 and 79,821 shares held by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F5]The shares are held as follows: 1,546,756 by BV IV QP, 59,585 by MPM BV IV KG, 43,977 by AM BV4 and 206,288 shares held by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F6]The shares were converted as follows: 260,003 by BV IV QP, 10,015 by BV IV KG, 7,392 by AM BV4 and 34,675 shares held by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F7]The shares are held as follows: 1,806,759 by BV IV QP, 69,600 by MPM BV IV KG, 51,369 by AM BV4 and 240,963 shares held by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Syndax Pharmaceuticals Inc

CIK 0001395937

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001395937

Filing Metadata

Form type: 4
Filed: Mar 8, 7:00 PM ET
Accepted: Mar 9, 4:42 PM ET
Size: 32.6 KB

View on SEC.gov